Drugs / [68Ga]Ga-DOTA-Cys-ATH001
[68Ga]Ga-DOTA-Cys-ATH001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06562361 | Aug 2024 → Dec 2025 overdue | Crohn disease, primary sclerosing cholangitis | Antaros Medical | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DOTA-Cys-ATH001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06562361 ↗ |
| Modality | Diagnostic / imaging agent | “PET-tracer” NCT06562361 ↗ |
| Route | Intravenous | “administered as an intravenous bolus dose.” NCT06562361 ↗ |